{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:02:27Z","timestamp":1790744547875,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T00:00:00Z","timestamp":1376006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2013.32","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T13:14:31Z","timestamp":1376054071000},"page":"e131-e131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model"],"prefix":"10.1038","volume":"3","author":[{"given":"E","family":"Decaup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Gravelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Fruchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Capilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Marrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Al Saati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F-X","family":"Frenois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Varoqueaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Savina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-J","family":"Fourni\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bezombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,9]]},"reference":[{"key":"BFbcj201332_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11901-005-0025-1","volume":"4","author":"DG Maloney","year":"2005","unstructured":"Maloney DG . Treatment of follicular non-Hodgkin\u2019s lymphoma. Curr Hematol Rep 2005; 4: 39\u201345.","journal-title":"Curr Hematol Rep"},{"key":"BFbcj201332_CR2","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","volume":"26","author":"B Bonavida","year":"2007","unstructured":"Bonavida B . Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629\u20133636.","journal-title":"Oncogene"},{"key":"BFbcj201332_CR3","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/1541-7786.MCR-11-0154","volume":"9","author":"C Bezombes","year":"2011","unstructured":"Bezombes C, Fourni\u00e9 JJ, Laurent G . Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives. Mol Cancer Res 2011; 9: 1435\u20131442.","journal-title":"Mol Cancer Res"},{"key":"BFbcj201332_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/asheducation-2010.1.265","volume":"2010","author":"TE Witzig","year":"2010","unstructured":"Witzig TE, Gupta M . Signal transduction inhibitor therapy for lymphoma. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 265\u2013270.","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"BFbcj201332_CR5","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.2010.32.7171","volume":"29","author":"D Mahadevan","year":"2011","unstructured":"Mahadevan D, Fisher RI . Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 2011; 29: 1876\u20131884.","journal-title":"J Clin Oncol"},{"key":"BFbcj201332_CR6","first-page":"280","volume":"18","author":"A Sawas","year":"2011","unstructured":"Sawas A, Diefenbach C, O'Connor OA . New therapeutic targets and drugs in non-Hodgkin's lymphoma. Curr Opin Hematol 2011; 18: 280\u2013287.","journal-title":"Curr Opin Hematol"},{"key":"BFbcj201332_CR7","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359\u20137368.","journal-title":"Oncogene"},{"key":"BFbcj201332_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","volume":"20","author":"RP Taylor","year":"2008","unstructured":"Taylor RP, Lindorfer MA . Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20: 444\u2013449.","journal-title":"Curr Opin Immunol"},{"key":"BFbcj201332_CR9","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U, Schmidt C, Herter S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393\u20134402.","journal-title":"Blood"},{"key":"BFbcj201332_CR10","first-page":"2143","volume":"119","author":"A Ivanov","year":"2009","unstructured":"Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119: 2143\u20132159.","journal-title":"J Clin Invest"},{"key":"BFbcj201332_CR11","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1182\/blood-2008-04-149161","volume":"112","author":"SA Beers","year":"2008","unstructured":"Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112: 4170\u20134177.","journal-title":"Blood"},{"key":"BFbcj201332_CR12","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","volume":"117","author":"W Alduaij","year":"2011","unstructured":"Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117: 4519\u20134529.","journal-title":"Blood"},{"key":"BFbcj201332_CR13","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","volume":"119","author":"J Honeychurch","year":"2012","unstructured":"Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012; 119: 3523\u20133533.","journal-title":"Blood"},{"key":"BFbcj201332_CR14","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/blood-2012-02-408773","volume":"119","author":"LH Sehn","year":"2012","unstructured":"Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012; 119: 5118\u20135125.","journal-title":"Blood"},{"key":"BFbcj201332_CR15","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","volume":"119","author":"G Salles","year":"2012","unstructured":"Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119: 5126\u20135132.","journal-title":"Blood"},{"key":"BFbcj201332_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1053\/gast.2001.27989","volume":"121","author":"G Klement","year":"2001","unstructured":"Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P et al. Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. Gastroenterology 2001; 121: 839\u2013852.","journal-title":"Gastroenterology"},{"key":"BFbcj201332_CR17","first-page":"3682","volume":"63","author":"V Dangles-Marie","year":"2003","unstructured":"Dangles-Marie V, Richon S, El-Behi M, Echchakir H, Doroth\u00e9e G, Thiery J et al. A three-dimensional tumor cell defect in activating autologous CTLs is associated with inefficient antigen presentation correlated with heat shock protein-70 down-regulation. Cancer Res 2003; 63: 3682\u20133687.","journal-title":"Cancer Res"},{"key":"BFbcj201332_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/jcp.20320","volume":"204","author":"S Ghosh","year":"2005","unstructured":"Ghosh S, Spagnoli GC, Martin I, Ploegert S, Demougin P, Heberer M et al. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 2005; 204: 522\u2013531.","journal-title":"J Cell Physiol"},{"key":"BFbcj201332_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/mc.20315","volume":"46","author":"M Zietarska","year":"2007","unstructured":"Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 2007; 46: 872\u2013885.","journal-title":"Mol Carcinog"},{"key":"BFbcj201332_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10549-009-0502-2","volume":"122","author":"B Weigelt","year":"2010","unstructured":"Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ . HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010; 122: 35\u201343.","journal-title":"Breast Cancer Res Treat"},{"key":"BFbcj201332_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/onc.2008.394","volume":"28","author":"M Pickl","year":"2009","unstructured":"Pickl M, Ries CH . Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009; 28: 461\u2013468.","journal-title":"Oncogene"},{"key":"BFbcj201332_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4161\/onci.19365","volume":"1","author":"P Gravelle","year":"2012","unstructured":"Gravelle P, Jean C, Valleron W, Laurent G, Fourni\u00e9 JJ . Innate predisposition to immune escape in follicular lymphoma cells. Oncoimmunology 2012; 1: 555\u2013556.","journal-title":"Oncoimmunology"},{"key":"BFbcj201332_CR23","first-page":"1627","volume":"47","author":"R Sutherland","year":"1987","unstructured":"Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach JP . Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res 1987; 47: 1627\u20131633.","journal-title":"Cancer Res"},{"key":"BFbcj201332_CR24","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","volume":"108","author":"L Leseux","year":"2006","unstructured":"Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108: 4156\u20134162.","journal-title":"Blood"},{"key":"BFbcj201332_CR25","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/nprot.2009.191","volume":"4","author":"F Debacq-Chainiaux","year":"2009","unstructured":"Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O . Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4: 1798\u20131806.","journal-title":"Nat Protoc"},{"key":"BFbcj201332_CR26","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.4049\/jimmunol.177.3.1581","volume":"177","author":"JM Irish","year":"2006","unstructured":"Irish JM, Czerwinski DK, Nolan GP, Levy R . Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006; 177: 1581\u20131589.","journal-title":"J Immunol"},{"key":"BFbcj201332_CR27","doi-asserted-by":"publisher","first-page":"12747","DOI":"10.1073\/pnas.1002057107","volume":"107","author":"JM Irish","year":"2010","unstructured":"Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci USA 2010; 107: 12747\u201312754.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201332_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature09663","volume":"469","author":"R Zhou","year":"2011","unstructured":"Zhou R, Yazdi AS, Menu P, Tschopp J . A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469: 221\u2013225, Erratum in: Nature 2011; 475: 122.","journal-title":"Nature"},{"key":"BFbcj201332_CR29","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2004-01-0277","volume":"104","author":"C Bezombes","year":"2004","unstructured":"Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, M\u00fcller S et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004; 104: 1166\u20131173.","journal-title":"Blood"},{"key":"BFbcj201332_CR30","doi-asserted-by":"crossref","unstructured":"D\u00e4britz JHM, Yu Y, Rosenfeldt MT, D\u00f6rken B, Schmitt CA . Anti-CD20 immunotherapy augments the chemotherapy-induced snescence response in human lymphoma cells. Blood (ASH Annual Meeting Abstracts) 2010; 182, (abstract 1827).","DOI":"10.1182\/blood.V116.21.1827.1827"},{"key":"BFbcj201332_CR31","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1182\/blood-2010-06-289736","volume":"116","author":"J Golay","year":"2010","unstructured":"Golay J, Bologna L, Andr\u00e9 PA, Buchegger F, Mach JP, Boumsell L et al. Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood 2010; 116: 3372\u20133373.","journal-title":"Blood"},{"key":"BFbcj201332_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2007-04-085092","volume":"111","author":"L Leseux","year":"2008","unstructured":"Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008; 111: 285\u2013291.","journal-title":"Blood"},{"key":"BFbcj201332_CR33","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","volume":"10","author":"S Dalle","year":"2011","unstructured":"Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011; 10: 178\u2013185.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj201332_CR34","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","volume":"24","author":"AR Jazirehi","year":"2005","unstructured":"Jazirehi AR, Bonavida B . Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121\u20132143.","journal-title":"Oncogene"},{"key":"BFbcj201332_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","volume":"152","author":"M Patz","year":"2011","unstructured":"Patz M, Isaeva P, Forcob N, M\u00fcller B, Frenzel LP, Wendtner CM et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152: 295\u2013306.","journal-title":"Br J Haematol"},{"key":"BFbcj201332_CR36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-L\u00f3pez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995\u20131001.","journal-title":"Ann Oncol"},{"issue":"1","key":"BFbcj201332_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/asheducation-2007.1.226","volume":"2007","author":"D. G. Maloney","year":"2007","unstructured":"Maloney DG . Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. Hematology (Am Soc Hematol Educ Program) 2007, 226\u2013232.","journal-title":"Hematology"},{"key":"BFbcj201332_CR38","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2008-08-175125","volume":"113","author":"D Dayd\u00e9","year":"2009","unstructured":"Dayd\u00e9 D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009; 113: 3765\u20133772.","journal-title":"Blood"},{"key":"BFbcj201332_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.tcb.2011.06.008","volume":"21","author":"S Hekimi","year":"2011","unstructured":"Hekimi S, Lapointe J, Wen Y . Taking a \"good\" look at free radicals in the aging process. Trends Cell Biol 2011; 21: 569\u2013576.","journal-title":"Trends Cell Biol"},{"key":"BFbcj201332_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2141.2008.07555.x","volume":"145","author":"J Turzanski","year":"2009","unstructured":"Turzanski J, Daniels I, Haynes AP . Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br J Haematol 2009; 145: 137\u2013140.","journal-title":"Br J Haematol"},{"key":"BFbcj201332_CR41","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","volume":"118","author":"G Niederfellner","year":"2011","unstructured":"Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger MO et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies. Blood 2011; 118: 358\u2013367.","journal-title":"Blood"},{"key":"BFbcj201332_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11523-011-0177-6","volume":"6","author":"C Delbaldo","year":"2011","unstructured":"Delbaldo C, Albert S, Dreyer C, Sablin MP, Serova M, Raymond E et al. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Target Oncol 2011; 6: 119\u2013124.","journal-title":"Target Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bcj201332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bcj201332","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:49:09Z","timestamp":1672958949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,9]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8]]}},"alternative-id":["BFbcj201332"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2013.32","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,9]]},"assertion":[{"value":"28 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ED, NV and AS are employees of Institut de Recherche Roche (Boulogne Billancourt, France), F. Hoffmann-La Roche AG (Basel, Swittzerland) and Roche S.A.S (Boulogne Billancourt, France) respectively. CK is an employee of Roche Glycart AG (Schlieren). SF received a grant from Roche. CB received research funding from Roche. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}